Michael Detke

1 presentation

• W1. THE PHASE 2/3 GAIN TRIAL OF THE FIRST-GENERATION P. GINGIVALIS GINGIPAIN INHIBITOR ATUZAGINSTAT IN MILD-TO-MODERATE PROBABLE ALZHEIMER’S DISEASE: NEW CEREBROSPINAL FLUID BIOMARKER DATA

  2026 ASCP Annual Meeting